Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Product Name : Folotyn
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2023
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pralatrexate injection is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Product Name : Pralatrexate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2017
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2017
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2015
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2013
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2011
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : New York University Cancer Institute | NYU Langone Health | National Comprehensive Cancer Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2010
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : New York University Cancer Institute | NYU Langone Health | National Comprehensive Cancer Network
Deal Size : Inapplicable
Deal Type : Inapplicable